{"product_id":"retatrutide-64mg-multi-dose-injection-pen","title":"Retatrutide 64mg Multi-Dose Injection Pen","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eBodyPharm's Retatrutide 64mg pen is a pre-filled, multi-dose subcutaneous delivery device formulated for laboratory and clinical research applications involving triple hormone receptor agonism. Each pen contains 64mg of retatrutide (LY3437943), a compound that simultaneously targets the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors — a mechanism of particular interest to researchers studying incretin-based metabolic pathways, energy expenditure, and glycemic regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eThe pen is formulated with disodium phosphate dihydrate, propylene glycol, phenol, and sterile water as excipients, supporting compound stability across the research handling process. Its multi-dose design (with clearly marked 2mg, 4mg, and 8mg dial increments) allows research teams to standardize dosing across study protocols without needing to reconstitute or measure from a vial, reducing variability introduced by manual preparation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eEach unit is single-patient\/single-subject use only, and ships in tamper-evident packaging with a batch reference (EU-0344-LAB4 Rv1.1) for traceability — an important consideration for institutions maintaining chain-of-custody documentation for research compounds.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eRetatrutide has drawn significant attention in metabolic research circles following Phase 2 and Phase 3 clinical trial data published in journals including the \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e and \u003cem\u003eNature Medicine\u003c\/em\u003e, which reported substantial effects on body weight, liver fat, and glycemic markers in trial populations. BodyPharm's research-grade formulation is intended to support continued investigation into these mechanisms by qualified laboratories, academic institutions, and licensed investigators.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48818135007457,"sku":null,"price":4480.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/fe36db60-9b4c-4848-971b-7859d606c303.png?v=1785413795","url":"https:\/\/health-tech.co.za\/products\/retatrutide-64mg-multi-dose-injection-pen","provider":"Health Tech","version":"1.0","type":"link"}